Setmelanotide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Setmelanotide (Setmelanotide (MC4R agonist)) is a Melanocortin-4 receptor agonist. Developed by Rhythm Pharmaceuticals as first-in-class MC4R agonist for genetic obesity. It is researched for weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction. Common dosages range from 1-3 mg daily administered once daily.
What Is Setmelanotide?
Setmelanotide (Setmelanotide (MC4R agonist)) is a Melanocortin-4 receptor agonist. Developed by Rhythm Pharmaceuticals as first-in-class MC4R agonist for genetic obesity. Also known as RM-493, Imcivree, it has been studied for its potential effects on weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction.
The only FDA-approved treatment specifically targeting genetic forms of obesity via MC4R agonism — addresses the root cause of hypothalamic obesity rather than symptomatic appetite suppression. In the research community, Setmelanotide has gained attention for its distinctive profile.
How Does Setmelanotide Work?
Directly activates melanocortin-4 receptors (MC4R) in the hypothalamic paraventricular nucleus, bypassing upstream leptin-POMC pathway defects. MC4R activation suppresses hunger signaling through AgRP neurons while activating POMC neurons, resulting in sustained satiety and increased energy expenditure independent of leptin pathway integrity.
This multi-pathway activity helps explain why Setmelanotide shows potential across several different applications.
What Does the Research Say About Setmelanotide?
Phase 3 TRANSCEND trial: -18.4% placebo-adjusted BMI reduction at 52 weeks. FDA approved November 2020 for genetic obesity (POMC/PCSK1/LEPR deficiency). March 2026 expanded for acquired hypothalamic obesity.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended Setmelanotide Dosage?
Standard Setmelanotide dosing: 1-3 mg daily, administered once daily via subcutaneous injection.
Half-life: not publicly disclosed. Cycle length: ongoing continuous therapy.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your Setmelanotide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Setmelanotide.
Open Calculator →What Are the Side Effects of Setmelanotide?
Hyperpigmentation (skin, moles, lips) most common — reversible upon discontinuation. Injection site reactions, nausea, headache. Generally well-tolerated.
Setmelanotide is fda-approved (imcivree) for genetic and acquired hypothalamic obesity. prescription medication.
Can You Stack Setmelanotide With Other Peptides?
Not typically stacked due to direct MC4R activation bypassing upstream defects.
What Is the Bottom Line on Setmelanotide?
Setmelanotide is a Melanocortin-4 receptor agonist researched for weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction. Standard protocols use 1-3 mg daily once daily for ongoing continuous therapy.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
Setmelanotide : Benefits, Dosage, Side Effects & Research
Related Reading
- Setmelanotide Dosage Guide
- Setmelanotide Benefits
- Setmelanotide Side Effects
- Setmelanotide Stacking Guide
- Setmelanotide Cycle Guide
- Setmelanotide Research
Research-Grade Sourcing
If you're going to research Setmelanotide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Setmelanotide?
Setmelanotide (Setmelanotide (MC4R agonist)) is a Melanocortin-4 receptor agonist. Developed by Rhythm Pharmaceuticals as first-in-class MC4R agonist for genetic obesity. It is researched for weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction.
What is the recommended Setmelanotide dosage?
Common dosages: 1-3 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing continuous therapy. Half-life: not publicly disclosed. Use our peptide calculator for exact reconstitution math.
What are the side effects of Setmelanotide?
Hyperpigmentation (skin, moles, lips) most common — reversible upon discontinuation. Injection site reactions, nausea, headache. Generally well-tolerated.
Is Setmelanotide safe?
Setmelanotide has shown a favorable safety profile in research. FDA-approved (Imcivree) for genetic and acquired hypothalamic obesity. Prescription medication. All research should follow appropriate safety protocols.